CSL's Seqirus delivers record number of flu vaccines despite pandemic, and now it's eyeing next-gen mRNA shots

Despite a global pandemic and social distancing measures threatening to hamper influenza vaccinations last season, CSL’s Seqirus managed to deliver a record number of flu shots—and it’s preparing to match that this season. For its U.S. market, the CDC switched its guidance and now advises that COVID-19 vaccines can be administered alongside flu vaccines, which could benefit flu vaccinations this fall since people can come in for both jabs at the same time. Seqirus also has its eyes on another vaccine platform: self-amplifying mRNA. In light of the highly effective mRNA shots against COVID-19 from Pfizer and Moderna, CSL is working on pushing out its own program it hopes will “address some of the challenges experienced with current generation mRNA vaccines,” CEO Paul Perreault said